Idronoxil novel formulation - Kazia Therapeutics

Drug Profile

Idronoxil novel formulation - Kazia Therapeutics

Alternative Names: NOX-66

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Noxopharm
  • Developer Children Cancer Institute; Kazia Therapeutics
  • Class Antineoplastics; Hormones; Isoflavones; Small molecules
  • Mechanism of Action Tumor-associated NADH oxidase-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Prostate cancer
  • Preclinical Glioma

Most Recent Events

  • 10 Jul 2018 Preclinical trials in Glioma in Australia (unspecified route)
  • 09 Jul 2018 Interim adverse events data from the phase Ib DARRT-1 trial in Prostate cancer released by Noxopharm
  • 01 Jun 2018 Interim adverse events and efficacy data from the phase Ib/IIa trial for Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top